Profiel
Holger Neecke is currently the Chief Executive Officer at Tethis SpA since 2022.
Prior to this, he worked as the Director-Investor Relations at AGC Biologics SpA from 2001 to 2010 and as the Senior Director-Business Development at Ablynx NV.
He completed his undergraduate degree at the University of Basel, his MBA at the University of Bocconi, and his doctorate at the University of Milan.
Actieve functies van Holger Neecke
| Bedrijven | Functie | Begin |
|---|---|---|
Tethis SpA
 Tethis SpA BiotechnologyHealth Technology Tethis SpA engages in the provision of nanobiotechnology solutions. It develops devices for liquid biopsy, molecular diagnostic, and proteomic and microbiology. The company was founded by Emanuele Barborini, Simone Vinati, and Massimo Gatelli in 2004 and is headquartered in Milan Italy. | Algemeen Directeur | 20-10-2022 |
Eerdere bekende functies van Holger Neecke
| Bedrijven | Functie | Einde |
|---|---|---|
| ABLYNX | Corporate Officer/Principal | - |
| MOLMED S.P.A. | Investor Relations Contact | - |
Opleiding van Holger Neecke
| University of Milan | Doctorate Degree |
| University of Basel | Undergraduate Degree |
| University of Bocconi | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
AGC Biologics SpA
 AGC Biologics SpA Pharmaceuticals: MajorHealth Technology AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy. | Health Technology |
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Tethis SpA
Tethis SpA BiotechnologyHealth Technology Tethis SpA engages in the provision of nanobiotechnology solutions. It develops devices for liquid biopsy, molecular diagnostic, and proteomic and microbiology. The company was founded by Emanuele Barborini, Simone Vinati, and Massimo Gatelli in 2004 and is headquartered in Milan Italy. | Health Technology |
